Analysts are predicting an 11% increase in VBK.
We have analyzed the trading prices of the holdings in our ETF coverage against the average analyst 12-month forward target price.
Analysts are predicting an 11% increase in VBK. Read More »
BBIO
Analysts provide perspectives on healthcare companies BridgeBio Pharma and Insmed.
Read More: https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bridgebio-pharma-bbio-and-insmed-insm?utm_source=alphanewsstream.com&utm_medium=referral
Analysts provide perspectives on healthcare companies BridgeBio Pharma and Insmed. Read More »
BridgeBio Pharma’s rating of “Buy” has been reaffirmed due to positive results from the ATTRibute-CM study.
Read More: https://www.tipranks.com/news/blurbs/buy-rating-affirmed-on-bridgebio-pharma-amid-promising-attribute-cm-study-results?utm_source=alphanewsstream.com&utm_medium=referral
BridgeBio Pharma’s “Buy Rating” has been confirmed due to positive results from the ATTRibute-CM study.
Read More: https://www.tipranks.com/news/blurbs/buy-rating-affirmed-on-bridgebio-pharma-amid-promising-attribute-cm-study-results?utm_source=alphanewsstream.com&utm_medium=referral
